Mammotome Introduces HydroMARK™ Plus with CE Mark for Enhanced Breast Biopsy Accuracy

Mammotome Advances Breast Biopsy Technology in Europe

Mammotome, a prominent name in breast care innovation and a part of Danaher Corporation, has just made significant strides in enhancing breast cancer diagnosis and treatment. The company announced the acquisition of the CE mark for its HydroMARK™ Plus Breast Biopsy Site Marker, positioning it to broaden access to this state-of-the-art technology across Europe.

Approval of the HydroMARK™ Plus marks a pivotal moment for patients undergoing breast cancer processes, reflecting Mammotome’s commitment to facilitate advancements in healthcare technologies that resonate globally. This innovative tool merges proprietary hydrogel technology with unique design features that improve marker stability and visibility, essential factors in ensuring precise clinical outcomes for patients.

Exceptional Design and Functionality

The introduction of the HydroMARK™ Plus markers is a game-changer in the industry; these products enhance tissue adherence and significantly reduce the risk of marker displacement during surgical excisions. At the heart of the design is a hydrogel carrier that hydrates within 24 hours, providing reliable ultrasound visibility for up to 12 months, a crucial trait for patients undergoing neoadjuvant chemotherapy. Moreover, the markers can be visualized not only through ultrasound but also via mammography and MRI, indicating a broad spectrum of applications within clinical practices.

Olaf Andrich, the General Manager for EMEA at Mammotome, emphasized the vital role of mitigating surgical displacement risks in guiding breast care teams as they provide treatment. He stated, "The HydroMARK™ Plus markers were engineered with stability and visibility in mind, instilling greater confidence in clinicians that the marker will remain aligned with the targeted tissue during surgery." This focus on precision is fundamental as it augments the quality of care provided to patients.

Comprehensive Breast Biopsy Site Marker Portfolio

The HydroMARK™ Plus markers are included in Mammotome's extensive breast biopsy site marker selection, ensuring medical professionals have options tailored to their clinical needs. With both FDA clearance and Health Canada approval, the HydroMARK™ Plus confirms Mammotome's ongoing dedication to broadening access to advanced breast care technologies, asserting its position as a leader in the market.

The rollout of the HydroMARK™ Plus markers across Europe is set to begin shortly, with a strategic phased approach targeting selected markets. This expansion will undoubtedly bolster the resources available to healthcare providers and improve patient outcomes.

About Mammotome

With headquarters in Cincinnati, Ohio, Mammotome has dedicated itself to fostering a compassionate and innovative environment for breast care. The company’s offerings span across over 65 nations, emphasizing their commitment to supporting physicians, clinicians, and patients alike. Their comprehensive product portfolio is aimed at optimizing the outcomes in breast care, coupled with a wealth of educational resources that assist in navigating the healthcare journey.

Mammotome's mission aligns with that of its parent company, Danaher, a leader in life sciences and diagnostics, dedicated to leveraging technology and science to enhance human health globally. With continuous innovation and a focus on operational excellence, Mammotome and Danaher collectively strive to build a healthier, sustainable tomorrow for all communities.

For more insights on the HydroMARK™ Plus markers and Mammotome’s products, visit their official website.